Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METRODIN vs CHORIONIC GONADOTROPIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Gonadotropin-releasing hormone (Gn RH) agonist; initially stimulates pituitary gonadotropin release, then downregulates Gn RH receptors, suppressing LH and FSH secretion.
Chorionic gonadotropin (h CG) binds to the luteinizing hormone/choriogonadotropin receptor (LHCGR) on the surface of gonadal cells, stimulating steroidogenesis and gametogenesis. In females, it triggers ovulation and luteinization; in males, it stimulates Leydig cells to produce testosterone.
Treatment of infertility: controlled ovarian hyperstimulation in assisted reproductive technology (ART),Ovulation induction in anovulatory women
FDA-approved: Induction of ovulation in infertile females (as part of controlled ovarian hyperstimulation),FDA-approved: Treatment of prepubertal cryptorchidism,FDA-approved: Treatment of hypogonadotropic hypogonadism in males,Off-label: Weight loss (not recommended),Off-label: In vitro fertilization protocols
750 mg intramuscularly twice weekly for 2-3 weeks; or 500 mg intramuscularly once weekly for 4-6 weeks.
For hypogonadotropic hypogonadism: 1000-2000 IU subcutaneously or intramuscularly 2-3 times per week. For ovulation induction: 5000-10,000 IU intramuscularly as a single dose.
Terminal elimination half-life is approximately 35 hours (range 28–48 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment.
Biphasic: initial half-life ~11 hours, terminal half-life ~23–30 hours. Single-dose half-life ~32 hours; repeated dosing may extend due to accumulation.
Metabolized via peptidases in the liver and kidneys; metabolites are inactive.
Primarily metabolized in the liver via proteolytic degradation; undergoes renal excretion with a half-life of 24-36 hours.
Primarily renal, with approximately 75% of a dose excreted unchanged in urine within 24 hours; biliary/fecal excretion accounts for less than 5% of elimination.
Primarily renal; intact h CG is excreted in urine. Negligible biliary/fecal elimination.
Approximately 30% bound to plasma proteins, predominantly albumin.
Approximately 80% bound; binds to albumin and sex hormone-binding globulin (SHBG) with low affinity.
Apparent volume of distribution is approximately 0.2 L/kg, indicating limited extravascular distribution and confinement primarily to the extracellular fluid space.
0.3–0.5 L/kg; distributes into extracellular fluid, gonadal tissues, and poorly into fat.
Subcutaneous administration: absolute bioavailability is approximately 75–80% due to partial presystemic degradation; intramuscular administration: bioavailability is similar, approximately 70–80%.
IM/SC: ~40% to 100% (mean ~78%) due to variable absorption; IV: 100% (not typical). Oral: negligible (<1% due to degradation).
GFR 10-50 m L/min: reduce dose to 500 mg intramuscularly twice weekly; GFR <10 m L/min: 500 mg intramuscularly once weekly.
No specific dose adjustment guidelines available; use with caution in severe renal impairment (GFR <30 m L/min/1.73 m²).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: contraindicated.
No specific dose adjustment guidelines available; use with caution in severe hepatic impairment (Child-Pugh class C).
Not recommended in pediatric patients; limited safety data available.
Cryptorchidism: 500-1000 IU subcutaneously or intramuscularly 2-3 times per week for 6 weeks. Delayed puberty: 500-1500 IU subcutaneously or intramuscularly 2-3 times per week.
Use with caution; dose adjustment based on renal function recommended; monitor for neurotoxicity.
No specific dose adjustments; monitor for fluid retention and cardiovascular effects.
Ovarian hyperstimulation syndrome (OHSS) and multiple births; increased risk of ovarian neoplasms.
None. However, use in females requires careful monitoring to avoid ovarian hyperstimulation syndrome (OHSS), which can be severe.
Ovarian hyperstimulation syndrome (OHSS), multiple gestation, ovarian torsion, pulmonary embolism, hypersensitivity reactions, and monitoring of ovarian response via ultrasound and estradiol levels.
Ovarian hyperstimulation syndrome (OHSS): Risk of severe OHSS with ascites, pleural effusion, and thromboembolic events,Multiple pregnancy: Increased risk due to ovulation induction,Thromboembolic events: Increased risk, especially in patients with prior history,Ovarian enlargement: Monitor with ultrasound,Hormonal-dependent malignancies: Caution in patients with prior history
Hypersensitivity to Gn RH or similar compounds, ovarian enlargement or cyst not due to polycystic ovary syndrome (PCOS), undiagnosed vaginal bleeding, primary ovarian failure, estrogen-dependent tumors (e.g., breast cancer), and pregnancy.
Pregnancy,Primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Active thromboembolic disorder,Hormone-sensitive tumors (e.g., prostate, breast, ovarian),Hypersensitivity to h CG or any component
Avoid all alcoholic beverages and any foods or medications containing alcohol (e.g., vinegar sauces, kombucha, some desserts) during therapy and for 48 hours post-treatment to prevent disulfiram-like reaction. No other significant food interactions.
No known food interactions.
Pregnancy Category X. In first trimester, risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and orofacial clefts. Second and third trimester exposure associated with fetal growth restriction, oligohydramnios, and neonatal hypotonia. Avoid throughout pregnancy.
Chorionic gonadotropin is a pregnancy hormone; exogenous use during first trimester may theoretically alter placental hormone balance, but no increased risk of congenital anomalies has been established. However, use during pregnancy is contraindicated except as part of assisted reproductive technology protocols where its role is physiological. No fetal risks documented from therapeutic use in second or third trimester.
No data on M/P ratio. Excretion into breast milk unknown. Due to potential for serious adverse reactions (CNS depression, respiratory depression) in breastfed infants, breastfeeding is contraindicated during therapy and for at least 7 days after last dose.
Chorionic gonadotropin is not orally bioavailable and is likely degraded in infant gastrointestinal tract. Excretion into breast milk is unknown; M/P ratio not established. However, due to its protein nature, transfer is expected to be minimal. Use during breastfeeding is not recommended unless clearly necessary; theoretical risk of hormonal effects on infant.
Not applicable; drug is contraindicated in pregnancy. No studies on pharmacokinetic changes. Do not dose during pregnancy.
No pharmacokinetic dose adjustments are recommended in pregnancy as the drug is typically administered only prior to conception or in early pregnancy for luteal phase support. The endogenous hormone levels in pregnancy far exceed exogenous doses. No dose modification required in later trimesters because use is contraindicated.
METRODIN (metronidazole) is a nitroimidazole antibiotic effective against anaerobic bacteria and protozoa. It achieves high concentrations in CNS and bone. Use with caution in patients with Cockayne syndrome due to risk of severe hepatotoxicity. Monitor INR closely in patients on warfarin as metronidazole potentiates anticoagulant effect. Dose adjustment required in severe hepatic impairment (Child-Pugh C).
Chorionic gonadotropin (h CG) is used to trigger ovulation in assisted reproduction and to treat hypogonadotropic hypogonadism in males. Monitor for ovarian hyperstimulation syndrome (OHSS) in women; discontinue if severe. Do not use in women with primary ovarian failure. In males, may cause gynecomastia or fluid retention.
Take exactly as prescribed; do not miss doses. Complete the full course even if you feel better.,Avoid alcohol and any products containing alcohol (e.g., mouthwash, cough syrup) during treatment and for at least 48 hours after last dose to prevent disulfiram-like reaction (nausea, vomiting, headache).,May cause metallic taste, dark urine, or gastrointestinal upset; these are usually harmless.,Inform your doctor if you have a history of liver disease, Cockayne syndrome, or are taking blood thinners (warfarin).,If you experience numbness/tingling in hands/feet, seizures, or confusion, seek medical attention immediately.
Report abdominal pain, bloating, nausea, vomiting, or rapid weight gain (signs of OHSS).,In males, report breast tenderness or swelling, or fluid retention (swollen ankles/feet).,Do not use if pregnant or breastfeeding unless directed by a specialist.,For fertility: timing of intercourse or IUI is critical; follow cycle monitoring closely.,In males: take as prescribed for testicular descent or hypogonadism; may require multiple doses.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METRODIN vs CHORIONIC GONADOTROPIN, answered by our medical review team.
METRODIN is a Gonadotropin that works by Gonadotropin-releasing hormone (Gn RH) agonist; initially stimulates pituitary gonadotropin release, then downregulates Gn RH receptors, suppressing LH and FSH secretion.. CHORIONIC GONADOTROPIN is a Gonadotropin Hormone that works by Chorionic gonadotropin (h CG) binds to the luteinizing hormone/choriogonadotropin receptor (LHCGR) on the surface of gonadal cells, stimulating steroidogenesis and gametogenesis. In females, it triggers ovulation and luteinization; in males, it stimulates Leydig cells to produce testosterone.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METRODIN and CHORIONIC GONADOTROPIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METRODIN is: 750 mg intramuscularly twice weekly for 2-3 weeks; or 500 mg intramuscularly once weekly for 4-6 weeks.. The standard adult dose of CHORIONIC GONADOTROPIN is: For hypogonadotropic hypogonadism: 1000-2000 IU subcutaneously or intramuscularly 2-3 times per week. For ovulation induction: 5000-10,000 IU intramuscularly as a single dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METRODIN and CHORIONIC GONADOTROPIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METRODIN is classified as Category C. Pregnancy Category X. In first trimester, risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and orofacial clefts. Second and third tri. CHORIONIC GONADOTROPIN is classified as Category C. Chorionic gonadotropin is a pregnancy hormone; exogenous use during first trimester may theoretically alter placental hormone balance, but no increased risk of congenital anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.